<DOC>
	<DOC>NCT01889290</DOC>
	<brief_summary>- Assessment of pharmacokinetic parameters of once daily subcutaneously administered methylnaltrexone in 10 evaluable neurointensive care patients. - Quantification of methylnaltrexone passage through the blood-brain-barrier in critically ill patients with severe cerebral affections. - Observation of laxation response after methylnaltrexone application and relation to plasma concentrations of methylnaltrexone. - Assessing the safety of once daily administered methylnaltrexone in neurointensive care patients. - Trial with medicinal product</brief_summary>
	<brief_title>Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients</brief_title>
	<detailed_description>After administration of methylnaltrexone s.c. multiple peripheral blood samples and additionally two liquor samples are drawn during a dose interval on day 1, 3, and 5 of drug administration.</detailed_description>
	<mesh_term>Sufentanil</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Inclusion criteria: hospitalisation in the neurointensive care unit deep sedation with sufentanil doses of = 40 mcg/h male or female aged 18 years or older females: negative pregnancy test Ventricular drainage as part of needed therapeutic measures Exclusion criteria: History of hypersensitivity to methylnaltrexone (RelistorÂ®) confirmed or suspected obstructive ileus or factors possibly leading to intestinal obstruction (e.g. an intestinal tumor) increased risk for patients with localized or diffused reduction in structural integrity of the gastrointestinal tract (e.g. peptic ulcer, acute diverticulitis) severe hepatic insufficiency (ChildPugh Class C) renal impairment (glomerular filtration rate &lt; 90 ml/min) with or without renal replacement therapy severe diarrhea despite high opioid dosing participation in another study with an investigational drug within the 30 days preceding and during the present study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>methylnaltrexone</keyword>
	<keyword>opioid-antagonist</keyword>
	<keyword>Obstipation</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>